V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330009184 | 330005983 | 1.84 | 12.3 | null | 2017-02-21 | 2017-03-01 | Bortezomib + CYCLOPHOSPHAMIDE | N | N | 330000343 | DHAP - R |
| 330009185 | 330005984 | 1.56 | 45 | Curative (C) | 2016-02-26 | 2016-03-10 | CNS LGG 2004 03 vinc weekly+ carbo | N | N | 330000343 | DHAP |
| 330009186 | 330005985 | 1.57 | 9.5 | Curative (C) | 2015-06-10 | 2015-06-10 | CNS LGG 2004 03 vinc weekly+ carbo | N | Y | 330000507 | IMATINIB |
| 330009187 | 330005988 | 0 | 90.1 | Palliative (P) | null | 2014-05-21 | Cyclophosphamide High Dose | null | N | 330000543 | UKALL XII |
| 330009188 | 330005988 | 1.73 | 71 | Curative (C) | 2017-05-26 | 2017-05-27 | AML 19 TRIAL | N | N | 330000543 | CAP |
| 330009189 | 330005990 | 1.59 | 61.5 | Palliative (P) | 2018-10-10 | 2018-10-25 | VIDE | 02 | N | 330000660 | ICE |
| 330009190 | 330005990 | 0 | 17.3 | Palliative (P) | 2016-06-17 | 2016-07-12 | CYTARABINE | N | N | 330000660 | IVA |
| 330009191 | 330005990 | 1.68 | null | Palliative (P) | 2017-07-05 | 2017-07-15 | Doxorubicin + Olaratumab | 2 | N | 330000660 | CYTARABINE |
| 330009192 | 330005991 | 1.59 | 56.2 | Not known (9) | 2015-02-04 | 2015-02-04 | CLADRIBINE | 02 | N | 330000770 | EMA/CO |
| 330009193 | 330005992 | 1.77 | 91 | Curative (C) | 2015-11-23 | 2015-12-04 | CVAD | 2 | N | 330000863 | CARBOPLATIN + VINCRISTINE |
| 330009194 | 330005993 | 1.77 | 106.3 | Curative (C) | 2015-12-24 | 2015-12-24 | GEMCITABINE | 02 | N | 330001004 | MVAC |
| 330009195 | 330005994 | null | 62.1 | Curative (C) | 2018-05-14 | 2018-05-22 | R GCVP | 02 | null | 330001004 | FLUOROURACIL + MITOMYCIN + RT |
| 330009196 | 330005995 | 1.52 | 106.7 | Palliative (P) | null | 2017-11-11 | BEP 5 Day | N | N | 330001080 | IFOSFAMIDE |
| 330009197 | 330005996 | 1.69 | 71.8 | Curative (C) | 2017-04-28 | 2017-04-29 | Cyclophosphamide + Vincristine | 2 | N | 330001370 | BENDAMUSTINE |
| 330009198 | 330009269 | 1.82 | 46.2 | Curative (C) | 2018-09-15 | 2018-10-05 | Dasatinib | N | N | 330001370 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 330009199 | 330009269 | 1.72 | 75.5 | Curative (C) | 2018-04-29 | 2018-05-01 | Dactinomycin + Vincristine | 02 | N | 330001370 | EMA/CO |
| 330009200 | 330005997 | 1.83 | 83.8 | Neo-adjuvant (N) | 2017-01-01 | 2017-01-11 | Cisplatin + Fluorouracil + RT 5day | 02 | null | 330002306 | IVA |
| 330009201 | 330005999 | 1.68 | 65 | Curative (C) | 2014-10-07 | 2015-03-03 | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE | Y | N | 330002485 | DOXORUBICIN + IFOSFAMIDE |
| 330009202 | 330006000 | 0 | 65 | Curative (C) | 2017-06-23 | 2017-06-24 | CISPLATIN + VINORELBINE | N | null | 330003175 | CHOP R |
| 330009203 | 330006001 | 1.6 | null | Curative (C) | 2017-09-24 | 2017-10-28 | Cyclophosphamide High Dose | Y | null | 330003750 | CISPLATIN + ETOPOSIDE + PACLITAXEL |
| 330009204 | 330006001 | 1.75 | 51.5 | Palliative (P) | 2018-10-23 | 2018-11-08 | ATG + Busulfan + Fludarabine | N | N | 330003750 | CYCLO + DOXORUBICIN + VINCRISTINE |
| 330009205 | 330011043 | 0 | 89 | Adjuvant (A) | 2016-06-20 | 2016-06-24 | Doxorubicin + Olaratumab | N | N | 330003920 | DOXORUBICIN + HD MTX |
| 330009206 | 330011043 | 1.7 | 60.2 | Curative (C) | 2016-08-30 | 2016-10-03 | Vincristine (weekly) | null | null | 330003920 | IFOSFAMIDE |
| 330009207 | 330006003 | 1.87 | 101 | Palliative (P) | 2017-10-07 | 2017-11-11 | Mitotane 5.5 - 10g | 01 | N | 330004392 | IFOSFAMIDE |
| 330009208 | 330006003 | 1.4 | 110 | null | 2017-12-20 | 2017-12-24 | Alemtuz+Fludara+Melphalan RIC MUD | N | N | 330004392 | DOXORUBICIN + IFOSFAMIDE |
| 330009209 | 330006004 | 0 | 61.7 | null | 2014-04-27 | 2014-05-06 | LIPOSOMAL DAUNORUBICIN | N | N | 330004663 | BEP |
| 330009210 | 330006009 | 1.58 | 73.85 | Curative (C) | 2015-07-17 | 2015-07-28 | BEP 5 Day | N | N | 330004773 | DOXORUBICIN + HD MTX |
| 330009211 | 330006010 | 1.77 | 36.4 | Disease modification (D) | 2015-03-22 | 2015-03-24 | Ifosfamide 3g/m2 5 day | N | N | 330004942 | BRENTUXIMAB |
| 330009212 | 330006011 | 1.79 | 13.5 | Curative (C) | 2015-12-21 | 2015-12-22 | FLUOROURACIL + MITOMYCIN + RT | 2 | N | 330004965 | RUXOLITINIB |
| 330009213 | 330006014 | 1.36 | 130.1 | Palliative (P) | 2016-01-08 | 2016-01-08 | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE | 02 | N | 330004965 | DOXORUBICIN + METHOTREXATE |
| 330009214 | 330006015 | 1.62 | 65.8 | Palliative (P) | 2016-01-20 | 2016-01-20 | Bortezomib +/- Dexamethasone | 02 | N | 330005116 | IFOSFAMIDE |
| 330009215 | 330009276 | 1.8 | 0 | Curative (C) | 2017-03-25 | 2017-04-29 | Cetuximab+Cisplatin+FU (> Cycle 2) | N | N | 330005116 | MITOTANE |
| 330009216 | 330012021 | 1.26 | 0 | Palliative (P) | null | 2018-05-19 | Gemcitabine weekly | null | N | 330005204 | RMS 2005 TRIAL |
| 330009217 | 330012021 | 1.6 | 102.2 | Curative (C) | 2017-11-12 | 2017-11-22 | CISPLATIN + CYCLO + DOXORUBICIN | 02 | N | 330005204 | CISPLATIN + ETOPOSIDE + PACLITAXEL |
| 330009218 | 330006017 | 0 | 54.7 | Palliative (P) | 2016-11-23 | 2019-02-18 | NB BEACON Temozolomide Bevacizumab | 02 | null | 330005446 | AML17 TRIAL |
| 330009219 | 330006017 | 0 | 47.5 | Curative (C) | 2015-08-06 | 2015-08-13 | CARBOPLATIN + Cetuximab + FLUOROURACIL | N | N | 330005446 | TRASTUZUMAB |
| 330009220 | 330006017 | null | 64.2 | Palliative (P) | 2018-09-09 | 2018-12-04 | Mitotane 5.5 - 10g | 02 | N | 330005446 | DOXORUBICIN + HD MTX |
| 330009221 | 330006019 | 1.82 | 66.6 | Curative (C) | 2017-10-03 | 2017-10-25 | ETOPOSIDE + IFOSFAMIDE + MTX | N | N | 330005775 | CARBOPLATIN + VINCRISTINE |
| 330009222 | 330009279 | 1.8 | 0 | Adjuvant (A) | 2018-07-07 | 2018-07-07 | BLEOMYCIN + CISPLATIN + VINCRISTINE | null | N | 330006301 | BENDAMUSTINE |
| 330009223 | 330006021 | 1.71 | 11.3 | Palliative (P) | 2015-07-05 | 2015-07-06 | Cyclophosphamide + Vincristine | N | N | 330006361 | RUXOLITINIB |
| 330009224 | 330006024 | 1.98 | 62 | Palliative (P) | null | 2017-12-29 | BEP 5 Day | Y | N | 330006361 | RUXOLITINIB |
| 330009225 | 330011054 | 1.82 | 74.6 | Palliative (P) | 2018-05-06 | 2018-05-19 | Doxorubicin + Ifosfamide | Y | N | 330006669 | GDP |
| 330009226 | 330009283 | 1.83 | 64.5 | Palliative (P) | 2017-06-25 | 2017-07-03 | DHAP | 02 | N | 330006773 | CETUXIMAB + CISPLATIN + FU |
| 330009227 | 330009283 | 0 | 75.9 | Curative (C) | 2018-07-09 | 2018-09-04 | UKALL XII Consolidation 2 & 4 | N | null | 330006773 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE |
| 330009228 | 330006027 | 1.75 | 61.6 | null | 2018-12-05 | 2018-12-05 | Ifosfamide | N | null | 330006932 | CISPLATIN + GEMCITABINE |
| 330009229 | 330006030 | 1.62 | 56.7 | Curative (C) | 2016-05-16 | 2016-05-19 | RUXOLITINIB | N | null | 330007206 | DOXORUBICIN + HD MTX |
| 330009230 | 330006030 | null | 61.2 | Curative (C) | 2016-08-07 | 2016-08-07 | CLADRIBINE | null | null | 330007206 | HYDROXYCARBAMIDE |
| 330009231 | 330012579 | 0 | 88.3 | Curative (C) | 2017-10-22 | 2017-10-22 | Hydroxycarbamide | 2 | N | 330007477 | CISPLATIN + GEMCITABINE |
| 330009232 | 330006031 | 1.68 | null | Palliative (P) | 2014-12-29 | 2015-01-12 | Cyclophosphamide TBI Allograft | 02 | N | 330007592 | CLOFARABINE |
| 330009233 | 330011058 | 1.6 | null | Curative (C) | 2018-07-06 | 2018-08-02 | Gemcitabine weekly | null | N | 330007632 | FIGARO TRIAL |